This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hall, E. D. Articles by Yonkers, P. A. Search for Related Content PubMed PubMed Citation Articles by Hall, E. D. Articles by Yonkers, P. A.

Stroke, Vol 19, 340-344, Copyright © 1988 by American Heart Association

ARTICLES

Attenuation of postischemic cerebral hypoperfusion by the 21- aminosteroid U74006F

ED Hall and PA Yonkers
Central Nervous System Diseases Research Unit, Upjohn Company, Kalamazoo, Michigan 49001.

The ability of the nonglucocorticoid 21-aminosteroid U74006F, a potent inhibitor of iron-dependent lipid peroxidation, to antagonize progressive brain hypoperfusion after a 5-minute episode of global brain ischemia was examined in alpha-chloralose-anesthetized cats. Immediately after a 5-minute episode of near-total tourniquet-induced brain ischemia, cortical blood flow returned to normal or above normal. Thereafter, cortical blood flow fell progressively to a level 71.7% below normal by 3 hours after ischemia. In contrast, in cats that received 1 mg/kg i.v. U74006F 15 minutes after the ischemic episode, cortical blood flow remained significantly greater than that seen in vehicle-treated cats. At 3 hours, cortical blood flow had declined by only 45.7% (p less than 0.04 compared with vehicle). In addition, U74006F treatment significantly improved postischemic maintenance of blood pressure and recovery of somatosensory evoked potentials and reduced postischemic arterial blood acidosis. U74006F had no effect on cortical blood flow, somatosensory evoked potentials, or blood pressure in nonischemic cats. Our results suggest that U74006F may be useful in the early treatment of global cerebral ischemia.

This article has been cited by other articles:

				Y. Numagami and S. T. Ohnishi S-Allylcysteine Inhibits Free Radical Production, Lipid Peroxidation and Neuronal Damage in Rat Brain Ischemia J. Nutr., March 1, 2001; 131(3): 1100S - 1105. [Abstract] [Full Text]

				R. Schmid-Elsaesser, S. Zausinger, E. Hungerhuber, N. Plesnila, A. Baethmann, and H.-J. Reulen Superior Neuroprotective Efficacy of a Novel Antioxidant (U-101033E) With Improved Blood-Brain Barrier Permeability in Focal Cerebral Ischemia Stroke, October 1, 1997; 28(10): 2018 - 2024. [Abstract] [Full Text]

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				Y. Tanoue, S. Morita, Y. Ochiai, M. Hisahara, M. Masuda, Y. Kawachi, R. Tominaga, and H. Yasui INHIBITION OF LIPID PEROXIDATION WITH THE LAZAROID U74500A ATTENUATES ISCHEMIA-REPERFUSION INJURY IN A CANINE ORTHOTOPIC HEART TRANSPLANTATION MODEL J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1017 - 1026. [Abstract] [Full Text]

				T. B. Muller, O. Haraldseth, R. A. Jones, G. Sebastiani, C. F. Lindboe, G. Unsgard, and A. N. Oksendal Perfusion and Diffusion-Weighted MR Imaging for In Vivo Evaluation of Treatment With U74389G in a Rat Stroke Model Stroke, August 1, 1995; 26(8): 1453 - 1458. [Abstract] [Full Text]